<DOC>
	<DOCNO>NCT01677741</DOCNO>
	<brief_summary>This 2-part , study determine safety , tolerability pharmacokinetics oral dabrafenib child adolescent subject advance BRAF V600 mutation-positive solid tumor . Part 1 ( dose escalation study ) identify recommend Part 2 ( tumor-specific expansion study ) dose regimen use dose-escalation procedure . Approximately 6 18 subject participate Part 1 receive start dose 3 mg/kg dose deescalate escalate 1.5 milligram ( mg ) /kilogram ( kg ) 6 mg/kg . Up 6 subject enrol one dose level dependent upon number subject current dose level , number subject experience dose limiting toxicity ( DLT ) current dose level , number subject enrol data pending current dose level . Escalation may proceed either maximum tolerate dose ( MTD ) establish , dose median pharmacokinetic parameter consistent exposure adult achieve . Cohorts may add order evaluate additional dose level . Part 2 consist four disease-specific cohort subject tumor know BRAF V600 activation ( pediatric low-grade glioma , pediatric high-grade glioma , Langerhans cell histiocytosis [ LCH ] , tumor melanoma papillary thyroid carcinoma [ PTC ] ) . Each cohort enroll least 10 subject pre-dose least 1 post-dose disease assessment . In part study , Day 1 , single first dose administer , repeat dose begin Day 2 . PK sample perform Day 1 Day 15 subject &gt; =25 kg weight . For subject &lt; 25 kg &gt; =10 kg weight , blood sample PK analysis collect Day 1 Day 15 . For subject &lt; 10kg weight , blood sample PK analysis collect repeated administration Day 15 . Safety tolerability assess throughout study . Treatment dabrafenib continue disease progression clinical benefit development unacceptable toxicity , withdraw consent begin new therapy . At end treatment , final study visit occur .</brief_summary>
	<brief_title>A Study Determine Safety , Tolerability Pharmacokinetics Oral Dabrafenib In Children Adolescent Subjects</brief_title>
	<detailed_description />
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Written inform consent sign informed consent and/or assent ( age appropriate ) obtain accord institutional guideline . Male female &gt; =12 month &lt; 18 year age time sign informed consent form . Recurrent disease , refractory disease , progressive disease receive least one standard therapy disease . Note : Subjects metastatic ( surgically unresectable ) melanoma enrol firstline treatment ; Melanoma subject CNS involvement may enrol . At least one evaluable lesion . BRAF V600 mutationpositive tumor confirm Clinical Laboratory Improvement Amendments ( CLIA ) approve laboratory equivalent ( local BRAF testing may subject subsequent verification centralize testing ; centralize test confirm V600E V600K mutation ) . Performance score &gt; =50 % accord Karnofsky/Lansky performance status scale ( subject performance status &lt; =50 % enrol subject 's confinement bed inability carry activity due solely cancerrelated pain , assess investigator ) . Females childbearing potential ( negative serum pregnancy test within 7 day prior first dose study medication ) must willing practice acceptable method birth control . Must adequate organ function define follow value : Adequate bone marrow function define asabsolute neutrophil count ( ANC ) &gt; =1000/ microliter ( µL ) , hemoglobin &gt; =8.0 gram ( g ) / deciliter ( dL ) ( may receive red blood cell transfusion ) , platelets &gt; =75,000/µL ( transfusion independent , define receive platelet transfusion within 7 day period prior enrollment ) . Adequate renal metabolic function define : calculate glomerular filtration rate ( eGFR ) ( Schwartz formula ) , radioisotope GFR &gt; =90 milliliters/minutes ( mL/min ) /1.73 meter square ( m^2 ) ; serum creatinine within institutional reference range upper limit normal ( age/gender , available ) . Adequate liver function define : bilirubin ( sum conjugate + unconjugated ) &lt; =1.5 x upper limit normal ( ULN ) age , aspartate aminotransaminase ( AST ) alanine transaminase ( ALT ) &lt; =2.5 x ULN ; AST/ALT may &lt; 5 x ULN baseline disease treatment involve liver ( require radiographic confirmation liver involvement ) . Adequate cardiac function define : leave ventricular ejection fraction ( LVEF ) either &gt; =50 % ECHO great institutional low limit normal ( LLN ) echocardiogram ( ECHO ) ( receive medication cardiac function ) , correct QT use Bazett 's ( QTcB ) interval &lt; 450 millisecond ( msec ) . Part 2 ONLY : Previous treatment dabrafenib , another RAF inhibitor , mitogenactivated protein kinase ( MEK ) inhibitor ( exception : prior treatment sorafenib permit ) . Malignancy OTHER BRAF mutant malignancy study . Had chemotherapy radiotherapy within 3 week ( 6 week nitrosoureas mitomycin C ) prior administration first dose study treatment . The subject receive investigational product within following time period prior first dose day current study : 28 day 5 halflives twice duration biological effect investigational product ( whichever warrant data ) . History another malignancy . Exception : ( ) Subjects successfully treat diseasefree 3 year , ( b ) history completely resect nonmelanoma skin cancer , ( c ) successfully treat situ carcinoma , ( ) CLL stable remission eligible . Current use prohibit medication herbal preparation require medication study . Unresolved toxicity great National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) v4.0 Grade 2 high previous anticancer therapy , include major surgery except opinion investigator clinically relevant give know safety/toxicity profile dabrafenib ( e.g. , alopecia and/or peripheral neuropathy relate platinum vinca alkaloid base chemotherapy ) . Has leukaemia . History allergic reaction attribute compound similar chemical biologic composition dabrafenib excipients . Autologous allogeneic stem cell transplant within 3 month prior enrolment [ NOTE : subject evidence active graph versus host disease exclude ] . History myocardial infarction , severe unstable angina , peripheral vascular disease familial QTc prolongation . Subjects abnormal cardiac valve morphology ( &gt; =grade 2 ) document echocardiogram ( NOTE : subject grade 1 abnormality [ i.e. , mild regurgitation/stenosis ] enter study ) . Subjects moderate valvular thickening . Known , uncontrolled cardiac arrhythmia ( except sinus arrhythmia ) within past 24 week Uncontrolled medical condition ( e.g. , diabetes mellitus , hypertension , liver disease uncontrolled infection ) , psychological , familial , sociological , geographical condition permit compliance protocol ; unwillingness inability follow procedure require protocol . Presence active GI disease condition ( e.g. , small bowel large bowel resection ) interfere significantly absorption drug . Hepatitis B Virus , Hepatitis C Virus infection ( subject laboratory evidence Hepatitis B Virus clearance may enrol ) . Pregnant female determine positive human chorionic gonadotropin ( hCG ) test screen prior dosing . Lactating female actively breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Children Adolescents</keyword>
	<keyword>BRAF</keyword>
	<keyword>dabrafenib</keyword>
	<keyword>dose escalation</keyword>
	<keyword>BRF116013</keyword>
	<keyword>V600-mutation positive</keyword>
	<keyword>BRF</keyword>
</DOC>